BridgeBio Oncology Therapeutics (BBOT) Change in Accured Expenses (2024 - 2026)
BridgeBio Oncology Therapeutics (BBOT) posted Change in Accured Expenses of $305000.0 for Q1 2026, down 98.28% sequentially from $17.7 million in Q4 2025, and up 115.89% YoY from $141278.6 in Q1 2025.
BridgeBio Oncology Therapeutics (BBOT) Change in Accured Expenses (2024 - 2026) Analysis & Trends
BridgeBio Oncology Therapeutics has reported Change in Accured Expenses for 3 years, with the latest figure at $305000.0 in Q1 2026.
- Quarterly Change in Accured Expenses rose 115.89% year-over-year to $305000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $19.9 million (up 1213.39% YoY) and the FY2025 annual result came in at $17.7 million, up 12435.46% from the prior year.
- Change in Accured Expenses eased to $305000.0 in Q1 2026 per BBOT's latest filing, from $17.7 million in the prior quarter.
- Over five years, Change in Accured Expenses peaked at $17.7 million in Q4 2025 and troughed at -$2.4 million in Q3 2025.
- A 3-year average of $2.0 million and a median of $55808.0 in 2024 frame the typical range for Change in Accured Expenses.
- The widest YoY moves for Change in Accured Expenses: up 7645.41% in 2025, down 23140.92% in 2025.
- Over 3 years, Change in Accured Expenses stood at -$1.9 million in 2024, then jumped by 1030.63% to $17.7 million in 2025, then sank by 98.28% to $305000.0 in 2026.
- According to Business Quant data, Change in Accured Expenses over the past three periods registered $305000.0, $17.7 million, and -$2.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 222.50 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 492.70 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 55.78 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 212.44 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 61.62 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 68.82 Mn |
| 10 | BridgeBio Oncology Therapeutics | 726.38 Mn | 500.67 Mn | - | 14.62 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 14.62 Mn |
| Jun 30, 2026 | 14.62 Mn |
| Mar 31, 2026 | 305,000.00 |
| Mar 31, 2026 | 305,000.00 |
| Dec 31, 2025 | 17.68 Mn |
| Dec 31, 2025 | 17.68 Mn |
| Sep 30, 2025 | -2.41 Mn |
| Sep 30, 2025 | -2.41 Mn |
| Jun 30, 2025 | 4.32 Mn |
| Jun 30, 2025 | 4.32 Mn |
| Mar 31, 2025 | -1.92 Mn |
| Mar 31, 2025 | -1.92 Mn |
| Dec 31, 2024 | -1.90 Mn |
| Dec 31, 2024 | -1.90 Mn |
| Sep 30, 2024 | 1.98 Mn |
| Sep 30, 2024 | 1.98 Mn |
| Jun 30, 2024 | 55,808.00 |
| Jun 30, 2024 | 55,808.00 |
| Mar 31, 2024 | 8,333.00 |
| Mar 31, 2024 | 8,333.00 |